342 related articles for article (PubMed ID: 29943152)
1. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
De Laurentiis M; Bonfadini C; Lorusso V; Cilenti G; Di Rella F; Altavilla G; Otero M; Ardizzoia A; Marchetti P; Peverelli G; Amoroso D; Vecchio S; Fiorio E; Orecchia S
Support Care Cancer; 2018 Dec; 26(12):4021-4029. PubMed ID: 29943152
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Chan A; Low XH; Yap KY
J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
[TBL] [Abstract][Full Text] [Related]
3. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
[TBL] [Abstract][Full Text] [Related]
4. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
[TBL] [Abstract][Full Text] [Related]
5. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
6. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
7. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
8. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO).
Aapro M; Caprariu Z; Chilingirov P; Chrápavá M; Curca RO; Gales L; Grigorescu AC; Huszno J; Karlínová B; Kellnerová R; Malejčíková M; Marinca M; Petru E; Płużanski A; Pokorná P; Pribulova Z; Rubach M; Steger GG; Tesařová P; Valekova L; Yordanov N; Walaszkowska-Czyz A
Eur J Cancer; 2022 May; 166():126-133. PubMed ID: 35290913
[TBL] [Abstract][Full Text] [Related]
9. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E
Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813
[TBL] [Abstract][Full Text] [Related]
10. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract][Full Text] [Related]
11. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G
JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
Rugo HS; Rossi G; Rizzi G; Aapro M
Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
[TBL] [Abstract][Full Text] [Related]
13. Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.
Yokoyama S; Tamaru S; Tamaki S; Nakanishi D; Mori A; Yamakawa T; Ao T; Sakata Y; Mizuno T; Iwamoto T; Watanabe K; Simomura M; Kawakami K; Konishi N; Kageyama S; Ohtani S; Yamada T; Ban S; Ooi K
Clin Breast Cancer; 2018 Apr; 18(2):e157-e165. PubMed ID: 28735677
[TBL] [Abstract][Full Text] [Related]
14. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
[TBL] [Abstract][Full Text] [Related]
16. Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience.
Hernandez Torres C; Mazzarello S; Ng T; Dranitsaris G; Hutton B; Smith S; Munro A; Jacobs C; Clemons M
Support Care Cancer; 2015 Nov; 23(11):3341-59. PubMed ID: 26108169
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.
Meattini I; Francolini G; Scotti V; De Luca Cardillo C; Cappelli S; Meacci F; Furfaro IF; Muntoni C; Scoccianti S; Detti B; Mangoni M; Nori J; Orzalesi L; Fambrini M; Bianchi S; Livi L
Med Oncol; 2015 Mar; 32(3):80. PubMed ID: 25698536
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
19. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
20. Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea.
Lee R; Ku M; Je NK
Support Care Cancer; 2024 Feb; 32(3):190. PubMed ID: 38400861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
